Donepezil-associated survival benefits among Alzheimer's disease patients are retained but not enhanced during COVID-19 infections.
Ther Adv Infect Dis
; 10: 20499361231174289, 2023.
Artículo
en Inglés
| MEDLINE | ID: covidwho-20230821
ABSTRACT
Background and Aim:
Donepezil is a front-line treatment for Alzheimer's disease. Donepezil treatment is associated with decreased risk of all-cause mortality. Specific protection is observed in pneumonia and cardiovascular disease. We hypothesized that donepezil treatment would improve mortality among Alzheimer's patients following infection with COVID-19. The objective of this study is to assess the influence of ongoing donepezil treatment on survival in Alzheimer's disease patients after polymerase chain reaction (PCR)-confirmed COVID-19 infection.Methods:
This is a retrospective cohort study. We conducted a national survey of Veterans with Alzheimer's disease to assess the influence of ongoing donepezil treatment on survival in Alzheimer's disease patients after PCR-confirmed COVID-19 infection. We assessed all-cause 30-day mortality stratified by COVID-19 infection and donepezil use, estimating odds ratios using multivariate logistic regression.Results:
Among people with Alzheimer's disease and COVID-19, all-cause 30-day mortality was 29% (47/163) for people taking donepezil compared with 38% (159/419) for those who were not. Among people with Alzheimer's disease without COVID-19, all-cause 30-day mortality was 5% (189/4189) for people taking donepezil compared with 7% (712/10,241) for those who were not. Adjusting for covariates, the decrease in mortality associated with donepezil did not differ between people with and without COVID-19 (interaction p = 0.710).Conclusion:
The known survival benefits of donepezil were retained but not found to be specific to COVID-19 among people with Alzheimer's disease.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Tipo de estudio:
Estudio de cohorte
/
Estudio observacional
/
Estudio pronóstico
Idioma:
Inglés
Revista:
Ther Adv Infect Dis
Año:
2023
Tipo del documento:
Artículo
País de afiliación:
20499361231174289
Similares
MEDLINE
...
LILACS
LIS